Über den Autor
Margaret W. Mann, Division of Dermatology, Washington University, St Louis, Missouri, USA
David R. Berk, Division of Dermatology, Washington University, St Louis, Missouri, USA
Daniel L. Popkin, Division of Dermatology, Washington University, St Louis, Missouri, USA
Susan J. Bayliss, Division of Dermatology, Washington University, St Louis, Missouri, US
Preface, xirnDedication, xiirnAbbreviations, xiiirnPart 1 General DermatologyrnWork-up Quick Reference, 3rnDirect immunofl uorescence - where to biopsy?, 3rnFalse positive/negative DIFs, 4rnBiopsy for GVHD, 4rnThe Dermatologic Differential Algorithm, 4rnAlopecia Work-Up, 5rnAssociations, 5rnCicatricial or non-cicatricial?, 5rnAphthosis Classifi cation and Workup, 9rnMorphologic classifi cation, 9rnClassifi cation by cause, 9rnWork-up for complex apthae, 9rnTreatment, 9rnAmyloidoses, 10rnXanthomas, 11rnHyperlipoproteinemias: Fredrickson Classifi cation, 12rnHistiocytosis, 13rnLupus Erythematosus, 17rnSystemic lupus erythematosus criteria (4 of 11), 17rnAcute cutaneous lupus erythematosus, 17rnSubacute cutaneous lupus erythematosus, 17rnChronic cutaneous lupus erythematosus, 17rnAutoantibody sensitivities and specifi cities, 18rnAntinuclear Antibodies, 20rnAutoantibodies in Connective Tissue Diseases, 21rnVasculitis, 22rnTreatment of ANCA-associated vasculitis, 22rnAnti-neutrophil cytoplasmic antibody, 23rnSmall vessel vasculitis, 24rnMedium (+/- small) vessel vasculitis, 26rnLarge vessel vasculitis, 27rnCryoglobulinemia, 28rnCTCL Classifi cation, 29rnMycosis fungoides variants, 29rnMF (TNMB) staging, 31rnMF treatment algorithm, 32rnCutaneous B-cell Lymphoma, 33rnLeukemia cutis, 33rnMonoclonal Gammopathies, 34rnMelanoma - Classifi cation, 35rnBreslow depth, 36rnMelanoma - staging and survival, 36rnMelanoma - treatment guidelines, 37rnInfectious Disease, 39rnViruses and diseases, 39rnHuman papillomavirus, 41rnOther viral diseases, 42rnMycoses, 45rnVector-borne diseases, 52rnCreatures in dermatology, 58rnImmunology, 63rnComplement, 63rnComplement defi ciencies, 64rnAngioedema and complement levels, 64rnTh profiles, 65rnBullous Disorders, 65rnIntracorneal/subcorneal, 65rnIntraepidermal blisters, 66rnSuprabasilar blisters, 66rnSubepidermal with little infl ammation, 66rnSubepidermal with lymphocytes, 67rnSubepidermal with eosinophils, 67rnSubepidermal with neutrophils, 67rnSubepidermal with mast cells, 68rnEpidermolysis bullosa, 68rnMajor bullous diseases - clinicopathologic fi ndings, 71rnGlands, 75rnDisorders or Drugs Associated with Skeletal, Ocular, and/or Nail Findings, 77rnDermatoses of Pregnancy, 88rnNeonatal Vesiculopustular Eruptions, 90rnGenital Ulcers, 95rnCommon Contact Allergens, 96rnFeatures suggestive of specifi c irritant/toxin, 100rnPlants and dermatoses, 100rnVitamin Defi ciencies/Hypervitaminoses, 103rnGenodermatoses, 107rnGene list, 107rnChromosome abnormalities, 133rnTumors, 134rnDisorders of cornifi cation, 136rnDisorders of hair, nail, ectoderm, 139rnTumor syndromes, 144rnDisorders of connective tissue, 146rnDisorders of metabolism, 149rnDisorders of pigmentation, 154rnDisorders of vascularization, 156rnImmunodefi ciency syndromes, 159rnMiscellaneous, 162rnDermoscopy, 163rnPathology, 165rnHistochemical staining, 165rnImmunohistochemical staining, 167rnPathologic bodies, 170rnOther derm path buzzwords, patterns, DDx, 175rnPart 2 SurgeryrnSurgical Margins Guidelines, 183rnIndications for Mohs micrographic surgery, 183rnGuideline for Prophylactic Antibiotics, 184rnAlgorithm for antibiotic prophylaxis, 185rnGuideline for Prophylactic Antivirals, 186rnAnesthetics, 186rnDose calculation, 186rnTumescent anesthesia, 186rnTopical anesthetic, 187rnAdverse reaction to local anesthetics, 187rnLocal anesthetic, 188rnNerve blocks, 189rnSurgical Anatomy, 189rnAnatomy of the face, 189rnAnatomy of the nail, 193rnDanger zones in surgery, 194rnDermatomal distribution of sensory nerves, 196rnAnatomy of the lower extremity venous system, 197rnCutaneous Reconstruction, 198rnUndermining depths in reconstruction, 199rnDangerzone of the neck: Erbs point, 196rnSecond intention, 199rnSimple linear closure, 200rnTransposition fl ap, 201rnAdvancement fl ap, 204rnInterpolation fl ap, 206rnRotation fl ap, 207rnSkin graft, 208rnSutures, 210rnAbsorbable, 210rnNon-absorbable, 211rnSuture removal time, 212rnElectrosurgery, 212rnWound Healing, 212rnWound dressing, 213rnAntiseptic Scrubs, 214rnLasers, 216rnLaser principles, 217rnThermal relaxation time, 217rnLaser treatment of tattoo pigment, 218rnPhotoinduced eye injury, 218rnPhotodynamic Therapy, 220rnBasic principles, 220rnApplications, 220rnPhotosensitizer properties and options, 220rnUV Spectrum, 222rnUV Protection Measurements, 223rnUV Associations/Specifi cities, 223rnGlogau Wrinkle Scale, 224rnFitzpatrick Skin Type, 224rnPeeling Agents, 224rnTCA peel, 225rnTCA peel frost level, 225rnJessner solution, 225rnBaker-Gordon phenol, 226rnCook total body peel, 226rnPre-peel prep, 226rnPost-peel wound care, 226rnBotulinum Toxin, 226rnBotox injection sites, 227rnFillers, 229rnSclerotherapy, 234rnDetermine vessel size using needle gauge, 236rnRecommended maximum effective concentration of sclerosant to minimize side effects, 236rnPart 3 Drugs and TherapiesrnMedication Quick Reference, 239rnTopical steroids, 239rnNon-steroidals, 240rnCommonly used drugs in dermatology, 240rnSystemic Medications, 243rnAntimalarials, 243rnImmunosuppressive agents, 244rnSystemic retinoids, 246rnBiologics, 247rnGeneral Reference, 249rnMetric measurements, 249rnDosage calculation, 249rnDrug dispensing and absorption, 249rnCorticosteroid, 249rnAcne - Topical, 250rnAntibiotics, 250rnKeratolytics, 250rnAcne - Systemic, 251rnAntibiotics, 251rnRetinoids, 252rnOthers, 252rnAlopecia, 252rnAnalgesics, 252rnAnesthetics - Topical, 253rnAntibiotics, 253rnTopical/Antiseptic, 253rnSystemic, 254rnAntibiotic preoperative prophylaxis, see p. 184rnAntibiotic regimens, 255rnSTDs, 257rnAntifungals, 257rnTopical, 257rnSystemic, 258rnAntifungal regimens, 260rnAntiparasitics, 261rnAntivirals, 262rnFor HSV labialis - topical agents, 262rnFor HSV 1 or 2 - oral agents, 262rnFor HSV disseminated disease, 262rnFor herpes zoster/VZV, 262rnFor genital warts, 263rnFor verruca vulgaris, 263rnFor molluscum, 263rnAntihistamines, 263rnSedating, 263rnNon-sedating, 264rnH2-blockers, 264rnAntipruritic, 264rnTopical, 264rnOral, 264rnBleaching Agents/Depigmenting Agents, 265rnTopical Chemotherapy, 266rnActinic keratoses (AK), 266rnBasal cell carcinoma (BCC) - superfi cial BCC, 266rnCTCL, 266rnTopical agents, 266rnOral agent, 266rnOther agent, 267rnPsoriasis, 267rnTopical agents, 267rnTar, 267rnSystemic agents, 267rnSeborrheic Dermatitis, 268rnHypertrichosis, 268rnHyperhidrosis, 268rnWound Care, 269rnVitamins/Nutritional Supplements, 269rnMiscellaneous Meds, 269rnCytochrome P-450 Interactions, 270rnPregnancy Categories of Commonly Used Dermatologic Agents, 272rnCommon Dermatologic Drugs and Teratogenic Effects, 273rnDermatologic Drugs Reportedly Associated with Contraceptive Failure, 273rnDrug Eruptions, 274rnChemotherapeutic Agents and Skin Changes, 277rnAntidote to extravasation of chemotherapeutic agents, 279rnUV Light Treatment, 279rnUVA/UVB dosing, 279rnNBUVB dosing, 280rnPUVA, 280rnWashington University Dermatology Toxic Epidermal Necrolysis (TEN) Protocol, 282rnDiagnosis of TEN, 282rnTriage algorithm for TEN patients, 283rnTreatment for all TEN patients, 283rnIndex, 287rnColor plate section can be found facing page 208
Because dermatology is a complex visual specialty that mixes medical and surgical approaches to management, trainees need fast access to a wide range of material. This concise new reference uses tables, algorithms, protocols, guidelines, and staging and scoring systems to present succinct guidance on best-practice patient care. Structured around three components -- medical, surgical, and pharmacological -- the book consolidates the core Board exam information residents most often look up. Handbook of Dermatology: A Practical Manual was road-tested as it was developed to ensure usefulness for dermatology residents, dermatologists, and family physicians.